Does the media favor VYGR or AMPH?

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 1 mentions for Voyager Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Voyager Therapeutics' score of 0.41 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VYGR or ESPR?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Esperion Therapeutics and 1 mentions for Voyager Therapeutics. Esperion Therapeutics' average media sentiment score of 0.51 beat Voyager Therapeutics' score of 0.41 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VYGR or CYRX?

In the previous week, CryoPort had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for CryoPort and 1 mentions for Voyager Therapeutics. CryoPort's average media sentiment score of 0.84 beat Voyager Therapeutics' score of 0.41 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLYM or VYGR?

In the previous week, Climb Bio had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.41 beat Climb Bio's score of 0.37 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VYGR or OCS more profitable?

Voyager Therapeutics has a net margin of -319.61% compared to Oculis' net margin of -8,460.67%. Voyager Therapeutics' return on equity of -55.97% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Voyager Therapeutics -319.61% -55.97% -43.12% Oculis -8,460.67% -56.78% -45.62%

Does the media refer more to VYGR or OCS?

In the previous week, Voyager Therapeutics and Voyager Therapeutics both had 1 articles in the media. Voyager Therapeutics' average media sentiment score of 0.41 beat Oculis' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Voyager Therapeutics (VYGR) Competitors

$3.05 -0.12 (-3.79%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$3.10 +0.05 (+1.51%)

As of 07:10 AM Eastern

Compare

VYGR vs. AMPH, ESPR, CYRX, CLYM, and OCS

Should you buy Voyager Therapeutics stock or one of its competitors? MarketBeat compares Voyager Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Voyager Therapeutics include Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), CryoPort (CYRX), Climb Bio (CLYM), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

How does Voyager Therapeutics compare to Amphastar Pharmaceuticals?

Voyager Therapeutics (NASDAQ:VYGR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Voyager Therapeutics' net margin of -319.61%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 440.98%. Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 12.07%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 1 mentions for Voyager Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Voyager Therapeutics' score of 0.41 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.56	-$119.72M	-$1.97	N/A
Amphastar Pharmaceuticals	$719.89M	1.20	$98.09M	$1.66	11.83

Voyager Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Voyager Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Esperion Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

In the previous week, Esperion Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Esperion Therapeutics and 1 mentions for Voyager Therapeutics. Esperion Therapeutics' average media sentiment score of 0.51 beat Voyager Therapeutics' score of 0.41 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Esperion Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Esperion Therapeutics has higher revenue and earnings than Voyager Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.56	-$119.72M	-$1.97	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Voyager Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Voyager Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 440.98%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Esperion Therapeutics has a net margin of 0.12% compared to Voyager Therapeutics' net margin of -319.61%. Esperion Therapeutics' return on equity of -0.14% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Voyager Therapeutics beats Esperion Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to CryoPort?

Voyager Therapeutics (NASDAQ:VYGR) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

CryoPort has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.56	-$119.72M	-$1.97	N/A
CryoPort	$182.94M	4.33	$78.30M	$1.35	11.64

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 440.98%. CryoPort has a consensus price target of $15.11, suggesting a potential downside of 3.81%. Given Voyager Therapeutics' higher probable upside, research analysts plainly believe Voyager Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Voyager Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

In the previous week, CryoPort had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for CryoPort and 1 mentions for Voyager Therapeutics. CryoPort's average media sentiment score of 0.84 beat Voyager Therapeutics' score of 0.41 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CryoPort has a net margin of 41.57% compared to Voyager Therapeutics' net margin of -319.61%. CryoPort's return on equity of -7.92% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
CryoPort	41.57%	-7.92%	-4.79%

Summary

CryoPort beats Voyager Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Climb Bio presently has a consensus price target of $21.73, indicating a potential upside of 77.80%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 440.98%. Given Voyager Therapeutics' higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Climb Bio has higher earnings, but lower revenue than Voyager Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Voyager Therapeutics	$40.37M	4.56	-$119.72M	-$1.97	N/A

In the previous week, Climb Bio had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.41 beat Climb Bio's score of 0.37 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Climb Bio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Climb Bio's return on equity of -31.45% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Climb Bio has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

Climb Bio beats Voyager Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Oculis?

Voyager Therapeutics (NASDAQ:VYGR) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Voyager Therapeutics and Voyager Therapeutics both had 1 articles in the media. Voyager Therapeutics' average media sentiment score of 0.41 beat Oculis' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Voyager Therapeutics has a net margin of -319.61% compared to Oculis' net margin of -8,460.67%. Voyager Therapeutics' return on equity of -55.97% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Oculis	-8,460.67%	-56.78%	-45.62%

Oculis has lower revenue, but higher earnings than Voyager Therapeutics. Oculis is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.56	-$119.72M	-$1.97	N/A
Oculis	$1.45M	469.04	-$119.44M	-$2.13	N/A

Voyager Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 440.98%. Oculis has a consensus target price of $38.33, suggesting a potential upside of 226.80%. Given Voyager Therapeutics' higher probable upside, equities analysts plainly believe Voyager Therapeutics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Voyager Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Voyager Therapeutics beats Oculis on 12 of the 16 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$191.54M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.55	20.49	27.07	23.95
Price / Sales	4.56	300.33	515.05	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.86	7.92	10.62	6.14
Net Income	-$119.72M	$23.81M	$3.60B	$331.74M
7 Day Performance	-3.48%	-1.09%	-1.26%	-1.82%
1 Month Performance	-18.01%	2.56%	1.07%	-1.45%
1 Year Performance	-3.79%	42.16%	23.63%	16.32%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	3.1033 of 5 stars	$3.05 -3.8%	$16.50 +441.0%	-5.9%	$191.54M	$40.37M	N/A	100	Analyst Forecast
AMPH Amphastar Pharmaceuticals	3.2197 of 5 stars	$19.29 +3.0%	$22.00 +14.0%	-4.8%	$825.42M	$719.89M	11.62	1,976
ESPR Esperion Therapeutics	2.8874 of 5 stars	$3.19 +0.3%	$5.54 +73.6%	N/A	$819.47M	$403.14M	N/A	200	High Trading Volume
CYRX CryoPort	3.1316 of 5 stars	$15.71 -2.8%	$15.11 -3.8%	+118.5%	$815.01M	$176.18M	11.64	1,186	News Coverage Positive News
CLYM Climb Bio	2.9542 of 5 stars	$13.21 -5.6%	$21.73 +64.5%	+709.3%	$801.68M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. AMPH, ESPR, CYRX, CLYM, and OCS

How does Voyager Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Voyager Therapeutics compare to Esperion Therapeutics?

Summary

How does Voyager Therapeutics compare to CryoPort?

Summary

How does Voyager Therapeutics compare to Climb Bio?

Summary

How does Voyager Therapeutics compare to Oculis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. AMPH, ESPR, CYRX, CLYM, and OCS

How does Voyager Therapeutics compare to Amphastar Pharmaceuticals?

Is VYGR or AMPH more profitable?

Do institutionals and insiders have more ownership in VYGR or AMPH?

Do analysts rate VYGR or AMPH?

Does the media favor VYGR or AMPH?

Which has stronger earnings and valuation, VYGR or AMPH?

Which has more volatility and risk, VYGR or AMPH?

Summary

How does Voyager Therapeutics compare to Esperion Therapeutics?

Does the media refer more to VYGR or ESPR?

Do institutionals & insiders hold more shares of VYGR or ESPR?

Which has stronger valuation & earnings, VYGR or ESPR?

Which has more volatility and risk, VYGR or ESPR?

Do analysts prefer VYGR or ESPR?

Is VYGR or ESPR more profitable?

Summary

How does Voyager Therapeutics compare to CryoPort?

Which has higher earnings & valuation, VYGR or CYRX?

Do analysts prefer VYGR or CYRX?

Which has more risk & volatility, VYGR or CYRX?

Does the media refer more to VYGR or CYRX?

Do institutionals & insiders hold more shares of VYGR or CYRX?

Is VYGR or CYRX more profitable?

Summary

How does Voyager Therapeutics compare to Climb Bio?

Do analysts prefer CLYM or VYGR?

Which has higher valuation and earnings, CLYM or VYGR?

Does the media prefer CLYM or VYGR?

Do insiders and institutionals believe in CLYM or VYGR?

Is CLYM or VYGR more profitable?

Which has more risk and volatility, CLYM or VYGR?

Summary

How does Voyager Therapeutics compare to Oculis?

Does the media refer more to VYGR or OCS?

Is VYGR or OCS more profitable?

Which has better valuation & earnings, VYGR or OCS?

Do analysts recommend VYGR or OCS?

Which has more risk and volatility, VYGR or OCS?

Do insiders & institutionals hold more shares of VYGR or OCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools